- A. Health Biotechnology
- Areas of activity
- In vitro diagnostics
Algenex develops and commercializes remarkably productive baculovirus-based technologies for the production of high quality recombinant proteins. It also manufactures difficult-to-produce, recombinant proteins for diagnostic products and vaccines, some of them immunologically potentiated by a novel, proprietary molecule.
Two technology platforms are the foundation of Algenex:
Top-Bac® - A proprietary expression cassette composed by several virus-derived regulatory elements that, when incorporated into the genome of a baculovirus vector, improves to unprecedented levels the productivity and quality of recombinant proteins produced by insect cells; and
IBES® - Based on the use of insect larvae as disposable, living biofactories that in combination with Top-Bac® lead to record productivities for a baculovirus-based expression system. This technology, pioneered by Algenex in Europe, allows for a rapid and linear scaling-up process; increases success with proteins difficult to express; and dramatically reduces the capital investment with respect to conventional bioreactor-based technologies.
Algenex´s key business lines are:
- Licensing its proprietary technology platforms to produce recombinant proteins, whether for investigational or commercial purposes;
- Contract manufacturing to supply diagnostic reagents and/or assisting in their development;
- Co-development of vaccines with suitable partners;
- Licensing its immunopotentiating molecule for its use in veterinary and human vaccines.